Body weight gain induced by antipsychotic drugs: Mechanisms and management

Acta Psychiatrica Scandinavica

Volumn 100, Issue 1, 1999, Pages 3-16

  Baptista, T ^a  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Androgens; Antipsychotic; Estradiol; Hypothalamus; Obesity; Prolactin

Indexed keywords

ANTIESTROGEN; DOPAMINE RECEPTOR; ESTRADIOL; HISTAMINE RECEPTOR; INSULIN; METFORMIN; NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT; SEROTONIN RECEPTOR; SULPIRIDE; TAMOXIFEN;

DIET RESTRICTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HYPERINSULINEMIA; HYPERPROLACTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 0033060332     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb10908.x     Document Type: Review

References (163)

1. PLANANSKY K. Changes in weight in patients receiving a tranquilizing drug. Psychiatr Quart 1958;32:289-303.
2. MEFFORD RB Jr, LABROSE EH, GAWIENOWSI AM. Influence of chlorpromazine on certain biochemical variables in chronic male schizophrenics. J Nerv Ment Dis 1958;127:167-179.
3. KLETT CJ, CAFFEY EM. Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 1960;2:102-108.
4. CAFFEY EM. Experiences with large-scale interhospital co-operative research in chemotherapy. Am J Psychiatry 1961;117:713-719.
5. GORDON HL, GROTH C. Weight change during and after hospital treatment. Arch Gen Psychiatry 1964;10:187-191.
6. AMDISEM A. Drug-produced obesity. Experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964;11:182-189.
7. SLETTEN IW, GERSHON S. The effect of chlorpromazine on water and electrolyte balance. J Nerv Ment Dis 1966;142:25-31.
8. SINGH MM, VERGEL DE Dios L, KLINE NS. Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 1970;9:562-570.
9. ANUMONYE A. ONIBUWE-JOHNSON T, MARINHO AA. Clinical trial of pimozine. West Afr J Pharmacol Drug Res 1976;3:17-24.
10. FALLLOON W, WATT D, SHEPHERD M. Pimozide and fluphenazine decanoate in continuation therapy. Psychol Med 1978;8:59-70.
11. BRANCHEY MH, LEE JH, AMIN R, SIMPSON GM. High- and low-potency neuroleptics in elderly psychiatric patients. J Am Med Assoc 1978;239:1860-1863.
12. JOHNSON DAW, BREEN M. Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 1979;59:525-528.
13. DOSS FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979;40:528-530.
14. MARRIOT P, PANSA M, HIEP A. Depot fluphenazine maintenance treatment and associated weight changes. Compr Psychiatry 1981;22:320-325.
15. COOKSON JC, KENNEDY NM, GRIBBON D. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Int Clin Psychopharmacol 1986;Suppl. 1:41-51.
16. SILVERSTONE T, SMITH G, GOODALL E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988;153:214-217.
17. McCREADIE RG, TODD N, LIVINGSTON M et al. A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand 1990;Suppl. 358:136-137.
18. COOKSON JC. Side-effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol 1991;Suppl. 2:524-530.
19. LAMBERTI JS, BELLNIER T, SCHWARKOPZ SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-690.
20. LEADBETTER, R, SHUTTY M, PAVALONIS D, VIEWEG V, HIGGINS P, DOWNS M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
21. KEKS N, McGRATH J, LAMBERT T et al. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 1994;90:358-365.
22. UMBRICHT DS, POLLACK S, KANE JM. Clozapine and weight gain. J Clin Psychiatry 1994;55:157-160.
23. HUMMER M, KEMMLER G, KURZ M, KURZTHALER I, OBERBAUER H, WOLFANG FLEISCHHACKER W. Weight gain induced by clozapine. Eur Neuropharmacol 1995;5:437-440.
24. BUSTILLO JR, BUCHANAN RW, IRISH D, BREIER A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153:817-819.
25. Eli Lilly & Company. Zyprexa (Olanzapine). Lilly Laboratory Monograph. Caracas, Venezuela: Eli Lilly & Company, 1996;71-72.
26. BEASLEY CM Jr, HAMILTON SH, CRAWFORD AM et al. Olanzapine versus haloperidol: acute phase results in the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137.
27. HOYBERG OJ, FENSBO C, REMVIG J, LINJAERDE O. SLOTH-NIELSEN M, SALVESEN Y. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402.
28. Janssen Pharmaceutics. Risperdal (Risperidone). Janssen Laboratory Monograph. Caracas, Venezuela: Janssen Pharmaceutics, 1995;25-33.
29. PENN JV, MARTINI J, RADKA D. Weight gain associated with risperidone. J Clin Psychopharmacol 1996;16:259-260.
30. BHAVNANI SM, LEVIN GM. Antipsychotic agents: a survey of the prevalence, severity and burden of side-effects. Int Clin Psychopharmacol 1996;11:1-12.
31. BRODKIN ES, McDOUGLE CJ, LECKMAN JF. Antipsychotic drugs in children and adolescents. In: CSERNANSKY JG, ed. Antipsychotics. Berlin: Springer, 1996;479-504.
32. WETTERLING T, MUSSIGBRODT H. Body weight increase: a side-effect of zotepin (Nipolept)? Nervenarzt 1996;67:256-261.
33. PEUSKENS J, LINK CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273.
34. LEE AM, KNOLL JL, SUPPES T. The atypical antipsychotic sertindole: a case series. J Clin Psychiatry 1997;58:410-416.
35. MISRA LK, ERPENBACH JE, HAMLYN H, FULLER WC. Quetiapine: a new atypical antipsychotic. SDJ Med 1998;51:189-193.
36. GOPALASWAMY AK, MORGAN R. Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 1985;72:254-258.
37. STEDMAN T, WELHAN J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993;162:249-250.
38. VERDOUX H, GONZALES B, TAKEI N, BOURGEOIS M. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord 1996;38:81-87.
39. BERNSTEIN JG. Management of psychotropic drug-induced obesity. In: BJÖRNTORP P, BRODOFF BN, ed. Obesity, Philadelphia, PA: J.B. Lippincott, 1992;445-453.
40. BRADY KT. Weight gain associated with psychotropic drugs. South Med J 1989;82:611-617.
41. BAPTISTA T, TENEUD L, CONTRERAS Q et al. Lithium and body weight gain. Pharmacopsychiatry 1995;28:35-44.
42. SUGERMAN AA, HERMAN J. Molindole: an indole derivative with antipsychotic activity. Clin Pharmacol Ther 1967;8:261-265.
43. GALLANT DM, BISHOP MP. Molindone: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res 1968;10:441-447.
44. ABUZZAHAB FS. Long-term use of molindone in schizophrenics. J Clin Pharmacol 1973;11:422-426.
45. GARDOS G, COLE JO. Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977;134:302-304.
46. PARENT NM, ROY S, SRAMEK J, LASWSON W, HERRERA J. Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm 1986;20:873-875.
47. KALUCY RS. Drug-induced weight gain. Drugs 1980;19:268-278.
48. ROBINSON RG, McHUGH PR, FOLSTEIN MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975;12:59-68.
49. JALENQUES Y, TAUVERON Y, ALBUISSON E, AUDY V, FLEURY-DUHAMEL N, COUDERT AJ. Weight gain as a predictor of long-term clozapine efficacy. CNS Drugs 1996;12:16-25.
50. LAWSON WB, KARSON CN. Clinical correlates of body weight changes in schizophrenia. J Neuropsychiatr Clin Neurosci 1994;6:187-188.
51. EPSTEIN FH. Epidemiology of obesity. In: BJÖRNTORP P, BRODOFF BN, ed. Obesity. Philadelphia, PA: J.B. Lippincott, 1992;330-342.
52. BAPTISTA T, LACRUZ A, MEZA T. Prevalence of obesity in outpatients receiving antipsychotic drugs: correlation with serum prolactin levels. Caracas, Venezuela: Regional Symposium of the World Federation of Societies of Biological Psychiatry. Caracas, Venezuela: Venezuelan Psychiatric Association Press, 1998;17.
53. STANTON JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472.
54. BJÖRNTORP P. Endocrine abnormalities of obesity. Metabolism 1995;44 (Suppl.):21-23.
55. KISSEBAH AH, KRAKOVER GR. Regional adiposity and morbidity. Physiol Rev 1995;74:761-798.
56. REAVEN GM, Barting Lecture 1988; role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
57. ECKEL, RH. Insulin resistance: an adaptation for weight maintenance. Lancet 1992;340:1452-1453.
58. PORETSKY L, CARLIN MF. The gonadotropic function of insulin. Endocrinol Rev 1987;8:132-136.
59. SWINBURN BA, NYOMBA BL, SAAD MF et al. Insulin resistance associated with lower rates of weight gain in Pima Indians. J Clin Invest 1991;88:168-173.
60. RAVUSSIN E. Metabolic differences and the development of obesity. Metabolism 1995;44:12-14.
61. 2 dopamine receptors involved? Pharmacol Biochem Behav 1987;27rt:399-405.
62. BAPTISTA T, PARADA MA, MURZI E. Puberty modifies sulpiride effects on body weight in rats. Neurosci Lett 1988;92:161-164.
63. PARADA MA, HERNANDEZ L, HOEBEL BG. Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats. Pharmacol Biochem Behav 1988;30:917-923.
64. PARADA MA, HERNANDEZ L, PAEZ X, BAPTISTA T, PUIG DE PARADA M, QUIJADA M. Mechanism of the sulpiride-induced obesity in rats. Pharmacol Biochem Behav 1989;33:45-50.
65. 2 dopamine receptor supersensitivity? Med Hypoth 1989;30:5-8.
66. BAPTISTA T, HERNANDEZ L, HOEBEL BG. Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus. Pharmacol Biochem Behav 1990;37:533-537.
67. BAPTISTA T, TENEUD L, HERNANDEZ L. Enhancement of amphetamine anorexia after chronic administration of sulpiride in rats. Pharmacol Biochem Behav 1993;45:45-49.
68. BAPTISTA T, MATA A, TENEUD L, QUIJADA M, HAN HW, HERNANDEZ L. Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 1993;45:50-53.
69. SILVA F, CATALAN M, HERNANDEZ L, TENEUD L, BAPTISTA T. Hyponatremia and neuroleptic-induced obesity in rats. Res Commum Mol Pathol Pharmacol 1994;85:237-240.
70. BAPTISTA T, LOPEZ MA, TENEUD L et al. Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 1997;30:35-43.
71. BAPTISTA T, ARAUJO DE BAPTISTA E, ALTEMUS M, WEISS SRB, HERNANDEZ L. Tamoxifen prevents sulpiride-induced obesity in rats. Pharmacol Biochem Behav 1997;57:215-222.
72. BAPTISTA T, ALBORNOZ MA, TENEUD L et al. Mechanism of the neuroleptic-induced obesity in female rats. Progr Neuropsychopharmacol Biol Psychiatry 1998;22:187-198.
73. BAPTISTA T, LA CRUZ A, HERNANDEZ L. Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug sulpiride. Pharmacol Toxicol 1998;24:706.
74. BAPTISTA T, LACRUZ A, HERNANDEZ L. Naltrexone does not prevent the obesity induced by antipsychotic drugs in rats. Neurosci Ann Meet 1998;24:706.
75. 2 receptor antagonist sulpiride. Exp Clin Endocrinol 1990;96:25-29.
76. WAGSTAFF AJ, FITTON A, BENFIELD P. Sulpiride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in schizophrenia. CNS Drugs 1994;2:313-333.
77. LEIBOWITZ SF. Neurochemical systems of the hypothalamus. Control of feeding and drinking behavior and water-electrolyte excretion. In: MORGANE P, PANKSEPP J. ed. Handbook of the hypothalamus. Vol. 3. New York: Marcel Dekker Inc., 1980;299-438.
78. HOEBEL BG, HERNANDEz L, MARK GP et al. Brain microdialysis as a molecular approach to obesity: serotonin dopamine cyclic-AMP. In: BRAY GA, RICQUIER D, SPIEGELMAN BM, ed. Obesity: towards a molecular approach. New York: Wiley-Liss, 1990;45-62.
79. SAMANIN R, GARATTINI S. Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 1993;73:63-68.
80. PARADA MA, HERNANDEZ L, DEGOMA E. Serotonin may play a role in the anorexia induced by amphetamine injections into the lateral hypothalamus. Brain Res 1992;577:218-225.
81. STROMBOM U, KROTKIEWSKI M, BLENNOW J, MANSSON JE, EKMAN R, BJORNTORP P. The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Int J Obes Relat Metab Disord 1996;20:361-368.
82. GOODALL E, OXTOBY C, RICHARDS R, WATKINSON G, BROWN D, SILVERSTONE T. A clinical trial on the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988;153:208-213.
83. OOMURA Y, ONO T, SUGIMORI M, NAKAMURA T. Effects of cyproheptadine on the feeding and satiety centers in the rat. Pharmacol Biochem Behav 1973;1:449-459.
84. 1) affects food intake in rats. J Nutr 1994;124:1029-1036.
85. SINGH K, SINGH PI. Effect of cimetidine on weight in rats. Ind J Med Sci 1995;49:257-260.
86. 2-receptor antagonist reduces food intake and weight gain in rats by non-gastric acid secretory mechanisms. Acta Physiol Scand 1997;161:489-494.
87. TUOMISTO L. Regulation of feeding behavior, with special reference to histamine. J Physiol Pharmacol 1994;45:469-477.
88. 1 dopamine receptors in rat hypothalamic perifornical area. Neurosci Lett 1986;67:159-162.
89. MURZI E, BAPTISTA T, HERNANDEZ L. Hypothalamic sites affecting masticatory neurons in rats. Brain Res Bull 1991;26:321-325.
90. EVANS KR, VACCARINO FJ. Intra-nucleus accumbens amphetamin: dose-dependent effects on food intake. Pharmacol Biochem Behav 1986;25:1149-1151.
91. HERNANDEZ L, HOEBEL BG. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci 1988;42:1705-1712.
92. SILVERSTONE T, FINCHMAN J, WELLS B, KYRIAKIDES M. The effect of the dopamine receptor-blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man. Neuropharmacology 1980;19:1235-1237.
93. 2 receptors in the body weight increase induced by systemic sulpiride. Physiol Behav 1991;50:1161-1165.
94. FITTON A, HEEL RC. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990;40:723-747.
95. ZIMMERMAN U, RECHLIN TH, PLASKACEWICZ GJ, BAROCKA A, WILDT L, KASCHKA P. Effect of Naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study. Biol Psychiatry 1997;41:747-749.
96. JOHNSON RD. Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Med Hypotheses 1995;45:491-497.
97. 5-enkephalin on feeding and temperature in the rat. Eur J Pharmacol 1983;4:595-601.
98. McLEAN S, HOEBEL BG. Feeding induced by opiates injected into the paraventricular hypothalamus. Peptides 1983;4:287-292.
99. FIGLEWICZ DP, SCHWARTZ MW, SEELEY RJ et al. Endocrine regulation of food intake and body weight. J Lab Clin Med 1996:127;328-332.
100. ROBERTS SR, GREENBERG AS. The new obesity genes. Nutr Rev 1996;99:41-49.
101. ATKINSON RL. Use of drugs in the treatment of obesity. Annu Rev Nutr 1997;17:383-403.
102. WOODS SC, SEELEY RJ, PORTE D, SCHWARTZ MW. Signals that regulate food intake and energy homeostasis. Science 1998;280:1378-1383.
103. CAMPFIELD LA, SMITH FJ, BURN P. Strategies and potential molecular targets for obesity treatment. Science 1998;280:1383-1387.
104. FREY P. Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment. Eur J Pharmacol 1983;95:87-92.
105. HUTCHINSON JB, STRUPISH J, NAHORSKI SR. Release of endogenous dopamine and cholecystokinin from rat striatal slices: effects of amphetamine and dopamine antagonists. Brain Res 1986;370:310-314.
106. ALTAR CA, BOYAR WC, OEI E, WOOD PL. Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release. Brain Res 1988;460:76-82.
107. GARVER DL, BEINFELD MC, YAO JK. Cholecystokinin, dopamine and schizophrenia. Psychopharmacol Bull 1990;26:377-380.
108. BACH FW, LANGEMARK M, EKMAN R, REHFELD JF, SCHIFTER S, OLESEN J. Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. Neuropeptides 1994;27:129-136.
109. SAKAI K, MAEDA K, CHIHARA K, KANEDA H. Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides 1995;29:157-161.
110. OBUCHOWICZ E. Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like inmunoreactivity in the rat hypothalamus. Neuropeptides 1996;30:471-475.
111. BROMHI T, BLUM WF, ZEIGLER A et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998;3:76-80.
112. FONTOBONNE A, CHARLES MA, JUHAN VAGUE I et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996;19:920-926.
113. VELAZQUEZ E, MENDOZA S, HARNER T, SOSA F, GLUECK CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;5:647-654.
114. VELAZQUEZ E, ACOSTA A, MENDOZA SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-395.
115. ERLE G, BASSO M, FEDERSPIL G, SICOLO N, SCANDELLARI C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacology 1977;11:15-18.
116. BAPTISTA T, MOLINA MG, MARTINEZ JL et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 1997;11:256-262.
117. AMMON HPT, ORCI L, STEINKE J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther 1973;187:423-429.
118. FOSS MC, PAULA FJ, PACCOLA GM, PICCINATO CE. Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol 1995;43:721-726.
119. CABRERA R, MAYOR P, FERNÁNDEZ-RUIZ J, CALLE C. Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia. Mol Cell Endocrinol 1988;58:167-173.
120. REISS PM, REHEIRO DE OLEVEIRA P, GUERRA RM, REISS AM, COIMBRA CC. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Life Sci 1996;58:155-161.
121. MATSUDA M, MORI T. Effect of estrogen on hyperprolactinemia-induced glucose intolerance in SHN mice. Proc Soc Exp Biol Med 1996;212:243-247.
122. GREEN AI, BROWN WA. Prolactin and neuroleptic drugs. Neurol Clin 1988;6:213-223.
123. SCAGLIONE R, AVERNA MR, DICHARA MA et al. Thyroid function and release of thyroid-stimulating hormone response and prolactin from the pituitary in obesity. J Int Med Res 1991;19:389-394.
124. MELTZER HY, GOODE D, SCHYVE PM, YOUNG M, FANG V. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136:1550-1555.
125. CRAWFORD AMK, BEASLEY CHM, TOLLEFSON GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
126. BEUMONT PJV, GELDER MG, FRIESEN HG et al. The effects of phenothiazines on endocrine function. I. Patients with inappropriate lactation and amenorrhoca. Br J Psychiatry 1974;124:413-419.
127. OADES RD, SCHEPKER R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 1994;19:373-385.
128. BAPTISTA T, REYES D, HERNANDEZ L. Reproductive hormones during antipsychotic treatment: relationship with body weight regulation. Pharmacol Biochem Behav 1999;62:409-417.
129. ATAYA K, MERCADO A, KARTAGINER J, ABBASI J, MOGHISSI KS. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 1988;50:876-881.
130. BAPTISTA T, ALASTRE, T, CONTRERAS Q et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 1997;30:250-255.
131. BEUMONT PJV, CORKERC S, FRIESEN HG et al. Effects of phenothiazines on endocrine function. II. Effects in men and post-menopausal women. Br J Psychiatry 1974;124:420-430.
132. WANG DY, DE STAVOLA BL, BULBROOK RD et al. The relationship between prolactin levels and risk of breast cancer in premenopausal women. Eur J Cancer Clin Oncol 1987;23:1541-1548.
133. FERREIRA MF, SORRINHO LG, PIRES JS, SILVA MES, SANTOS MA, SANTOS MFF. Endocrine and psychological evaluation of women with recent weight gain. Psychoneuroendocrinology 1995;20:53-63.
134. CREEMERS LB, ZELISSEN PMJ, VANT VERLAAT JW, KOPPESCHAAR HPF. Prolactinoma and body weight: a retrospective study. Acta Endocrinol 1991;125:293-396.
135. GERARDO-GETTENS T, MOORE BJ, STERN JS, HORWITZ BA. Prolactin stimulates food intake in a dose-dependent manner. Am J Physiol 1989;256:276-280.
136. MOORE, BJ, GERARDO-GETTENS T, HORWITZ BA, STERN JS. Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 1986;17:563-569.
137. DEMURA R, ONO M, DEMURA H, SHIZUME K, OOUCHI H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17β estradiol in the human ovary. J Clin Endocrinol Metab 1982;99:1246-1250.
138. DORRINGTON J, GORE-LANGTON RE. Prolactin inhibits oestrogen synthesis in the ovary. Nature 1981;290:600-602.
139. LEE VANCE M, THORNER MO. Prolactin: hyperprolactinemic syndromes and management. In: WILSON JD, FOSTER DN, ed. Williams textbook of endocrinology. Philadelphia, PA: W.B. Saunders, 1992;394-403.
140. WADE GN, GRAY JM. Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol Behav 1979;22:583-594.
141. WADE GN, SCHNEIDER JE. Metabolic fuels and reproduction in female mammals. Neurosci Biobehav Rev 1992;16:235-272.
142. BJÖRNTORP P. Regional obesity. In: BJÖRNTORP P, BRODOFF BN, ed. Obesity. Philadelphia. PA: J.B. Lippincott, 1992;579-586.
143. BASKIN DG, NORWOOD BJ, SCHWARTZ MW, KOERKER DJ. Estradiol inhibits the increase of hypothalamic neuropeptide Y messenger ribonucleic acid expression induced by weight loss in ovariectomizcd rats. Endocrinology 1995;136:5547-5554.
144. SHIMIZU H, OHTANT K, KATO Y, TANAKA Y, MORI M. Withdrawal of estrogen increases hypothalamic neuropeptide y (NPY) mRNA expression in ovariectomized obese rat. Neurosci Lett 1996;204:81-84.
145. BIEGON A, PARSONS B, KREY LC, KAMEL F, McEWEN BS. Behavioral and neuroendocrine effects of long-term progesterone in the rat. Neuroendocrinology 1983;37:332-339.
146. AMATAYAKUL K, SIVASOMBOON B, THANANGKUL O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 1980;22:605-622.
147. MAINWARING R, HALES HA, STEVENSON K et al. Metabolic parameters, bleeding, and weight changes in US women using progestin-only contraceptives. Contraception 1995;51:149-153.
148. ADVIS JP, RICHARDS JS, OJEDA SR. Hyperprolactinemia-induced precocious puberty: studies on the mechanism(s) by which prolactin enhances ovarian progesterone responsiveness to gonadotropins in prepubertal rats. Endocrinology 1981;108:1333-1342.
149. GHOSH D, BISWAS NM, GHOSH PK. Studies on the effect of prolactin treatment on testicular steroidogenesis and gametogenesis in lithium-treated rats. Acta Endocrinol 1991;125:313-318.
150. CORREA N, OPLER LA, KAY SR, BIRMAHER B. Amantadine in the treatment of neuroendocrine side-effects of neuroleptics. J Clin Psychopharmacol 1987;7:91-95.
151. EBELING P, KOIVISTO VA. Physiological importance of dehydroepiandrosterone. Lancet 1994;343:1479-1481.
152. RINTERIS P, MARKIANOS M, HATZIMANOLIS J, STEFANIS C. A psychoendocrine study in male paranoid schizophrenics with delusional ideas of homosexual content. Acta Psychiatr Scand 1985;3;309-314.
153. GENTRY, RT, WADE GN. Androgenic control of food intake and body weight in male rats. J Compr Physiol Psychol 1976;90:18-25.
154. OKONMAH AD, BRADASHAW WG, COUCEYRO P, SALIMAN KFA. The effect of neuroleptic drugs on serum level in the male rat. Gen Pharmacol 1986;17:235-239.
155. BUCHANAN RW, CARPENTER WT. Targeted maintenance treatment in schizophrenia: issues and recommendations. CNS Drugs 1996;5:240-245.
156. SILVER H, GERAISY FN. Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study. J Clin Psychopharmacol 1997;16:463-464.
157. LEVI-MINZI S, BERMANZOHN PC, SIRIS SG. Bromocriptine for negative schizophrenia. Compr Psychiatry 1991;32:210-216.
158. CONNOLLY HM, CRARY JL, McGooN MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J 1997;337:581-588.
159. JOHNSON MP, NICHOLS DE. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol Biochem Behav 1990;36:105-109.
160. US Department of Health and Human Services. Interim public health recommendations, November 1997. Cardiac valvulopathy vaivulopathy associated with exposure to fenfluramine or dexfenfluramine. Morbidity Mortality Weekly Report 1997;46:1061-1066.
161. BELL PM, HADDEN DR. Metformin. Endocrinol Metab Clin North Am 1997;26:523-537.
162. KULKARNI J, DECASTELLA A, SMITH D,0 TAFFE J, KEKS N, COPOLOv D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20:247-252.
163. JORDAN VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-518.